Ultra Long Acting Insulin Degludec Reduces Nocturnal Hypoglycemia

[Northerner]

Two new phase 3 studies published in The Lancet show that ultra long acting insulin, Degludec, an investigational compound from Novo Nordisk, significantly reduces the rates of nocturnal hypoglycemia by 25%, compared to insulin glargine.

http://asweetlife.org/a-sweet-life-...octurnal-hypoglycemia-new-studies-show/26638/

 

[trophywench]

In type 2 patients, a significantly lower rate of overall hypoglycemic events was seen in the insulin degludec group, compared to those taking insulin glargine (11.1 vs. 13.6 episodes/patient-year). In the type 1 diabetes group the rate of hypoglycemia was comparable between the two treatment arms.

The rate of hypoglycemia at night was 25% lower in both type 1 and type 2 diabetes for patients treated with insulin degludec, compared to those taking insulin glargine (4.4 vs. 5.9 episodes/patient-year and 1.4 vs. 1.8 episodes/patient-year respectively).

Does para 2 contradict para 1? - in the first one they seem to be saying no difference between Lantus and Deg, but in the second there is.



Oh hang on; less hypos at night but no difference overall so that must mean more in the daytime?

or what?


Still confused !